Reply
- PMID: 38069978
- DOI: 10.1016/j.jaci.2023.10.030
Reply
Conflict of interest statement
Disclosure statement Disclosure of potential conflict of interest: T. B. Casale reports serving as a consultant and/or adviser for ARS Pharmaceuticals, Greentech, and Novartis. A. K. Ellis and M. Kaliner report serving as a consultant and/or adviser for ARS Pharmaceuticals. R. Lowenthal and S. Tanimoto are employees of ARS Pharmaceuticals. A. Nowak-Wegrzyn declares no relevant conflicts of interest.
Comment on
-
The risk of severe adverse reactions to neffy intranasal epinephrine spray.J Allergy Clin Immunol. 2024 Feb;153(2):535-536. doi: 10.1016/j.jaci.2023.11.015. Epub 2023 Dec 6. J Allergy Clin Immunol. 2024. PMID: 38069977 No abstract available.
References
Publication types
LinkOut - more resources
Full Text Sources